Nintedanib (Ofev) for Idiopathic Pulmonary Fibrosis (IPF)

Type: drug

Status: FDA Approved (for IPF, off-label consideration for asbestosis fibrosis)

Developer: Boehringer Ingelheim

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026